NMD4C Provides Opportunity for Neuromuscular Fellows to Build Clinical Network at National Meeting

The NMD4C Curriculum and Education task has worked to provide education and training support for Canadian neuromuscular clinical fellows. We seek to continuously improve the resources we provide to clinical trainees, and feedback from fellows identified a need for neuromuscular fellows in Canada to meet and forge connections with other fellows and clinicians from across the country.

To meet this need, we are pleased to share that this fall we provided an opportunity for clinical neuromuscular fellows to attend NMD4C’s annual meeting and the Western Canadian Neuromuscular Conference (WCNMC) in Calgary. Led by NMD4C and MDC fellowship recipient Dr Marianne Nury and University of Calgary Neuromuscular and EMG fellowship director Dr Gord Jewett, we support 16 fellows to attend both meetings and provided them with the opportunity to:

  • Present flash talks to introduce themselves to the other fellows and NMD4C investigators at our annual meeting
  • Present cases for discussion at the WCNMC
  • Attend networking events for fellows at the beginning and end of the WCNMC
  • Participate in the WCNMC research symposium – congratulations to Dr Lola Lessard, clinical fellow at The Ottawa Hospital who won “Best Poster Presentation”!

Following the success and positive reception of this event, we will look to provide future opportunities for Canadian neuromuscular fellows to attend similar events.

Canadian neuromuscular fellows attend the WCNMC in Calgary, AB.

Read next...

Hope On The Horizon: Trials Treatments and Therapies for DMD, DM1 and MG

Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG

Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!

Website - 2026 NMD4C Awards Now Open

2026 Awards Now Open for Nominations!

We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.

AGAMREE (vamorolone) Approved treatment for DMD in Canada

A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada

Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.